Does Cosentyx Reduce Vaccine Effectiveness?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, impairs immune responses to certain vaccines. It blunts antibody production against non-live vaccines like influenza and pneumococcal, with studies showing 20-40% lower seroprotection rates compared to placebo.[1][2]
Evidence from Clinical Trials
In phase 3 trials, patients on Cosentyx had reduced antibody titers after influenza vaccination (e.g., 52% seroprotection vs. 70% in controls for H1N1 strain) and pneumococcal vaccine (lower geometric mean titers).[1] A real-world study confirmed similar gaps for COVID-19 vaccines, with Cosentyx users showing 15-25% lower neutralizing antibodies post-booster.[3] Live vaccines like MMR or varicella are contraindicated due to infection risk.[1]
Which Vaccines Are Affected Most?
| Vaccine Type | Impact with Cosentyx | Recommendation |
|--------------|----------------------|---------------|
| Inactivated (e.g., flu, pneumococcal, COVID-19) | Moderate reduction in response | Vaccinate, but test response if high-risk |
| Live (e.g., yellow fever, shingles) | High risk; avoided | Do not use during treatment |
| Tdap or HPV | Minimal data; likely reduced | Consider pre-treatment vaccination |
Effect is dose- and duration-dependent, strongest after 3+ months of therapy.[2]
Timing Vaccines Around Cosentyx Doses
Vaccinate before starting Cosentyx if possible—ideally 4 weeks prior. If on treatment, give non-live vaccines anytime, but hold live vaccines until 4-6 weeks post-discontinuation. Response may improve 3-6 months after stopping.[1][4]
Patient Risks and Monitoring
Immunocompromised patients (e.g., elderly or with comorbidities) face higher breakthrough infection risk. Clinicians monitor titers in high-stakes cases, like healthcare workers. No increased severe infection rates from routine vaccines in trials, but efficacy gaps persist.[2][3]
Alternatives for Immunosuppressed Patients
Switch to biologics with less vaccine interference, like guselkumab (IL-23 inhibitor), which preserves flu vaccine response better (70-80% seroprotection).[5] Smallpox/mpox vaccines show similar impairments across IL-17/IL-23 classes.[6]
[1]: Cosentyx Prescribing Information, Novartis, 2023. https://www.cosentyx.com
[2]: Bagel et al., J Am Acad Dermatol, 2020. PubMed
[3]: Furer et al., Rheumatology, 2022 (COVID-specific). PubMed
[4]: CDC ACIP Guidelines on Immunization for Immunocompromised Adults, 2023. CDC
[5]: Mease et al., Lancet Rheumatol, 2021. PubMed
[6]: CDC Advisory on JYNNEOS Vaccine in IL-17 Users, 2023. CDC